IDNA Ishares Gold Trust Genomics Immunology And Healthcare Etf
- 25.065
- +0.331+1.34%
Gilead Sciences in Charts: Revenue From Major Products Rises Y/Y in Q3
Gilead Rises as It Raises 2024 Sales, Non-GAAP EPS Outlook
Gilead Sciences Raises FY24 Product Sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B
Revolution Medicines GAAP EPS of -$0.94 Misses by $0.04
Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.
Gilead Sciences Non-GAAP EPS of $2.02 Beats by $0.47, Revenue of $7.55B Beats by $550M
Breaking Down BioNTech: 16 Analysts Share Their Views
Tango Stock Plunges 28% Amid Pipeline Updates, Q3 Earnings Report
Arcus Says Gilead-partnered Cancer Therapy Cut Death Risk by 36%
Arcellx Issues Updates on Anito-cel Clinical Trials
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Gilead Sciences's Earnings: A Preview
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○ List of buy converted stocks in the market Code Stock name End price SAR TSE main board ＜1332＞ Nissui 938 886 ＜1605＞ INPEX 2009 1916 ＜1939＞ Yondenko 1360 1209 ＜1941＞ Chudenko 3385 3130 ＜1976＞ Myojo Kogyo 1319 1260 ＜1980＞ DaiDan 3020 2831 ＜2060＞ Feed One 8428 10 ＜2124＞ J
Syndax, Royalty Pharma Enter Into $350M Royalty Funding Deal
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
BioNTech Analyst Ratings
BioNTech Re-confirms Guidance Of Planned Full Year 2024 R&D Expenses Of €2.4B-2.6B And Reduced Guidance Range For SG&A Expenses To €600M-700M And For Capital Expenditures For Operating Activities To €300M-400M
BioNTech Shares Are Trading Higher After the Company Reported Q3 Financial Results.
BioNTech Q3 2024 GAAP EPS €0.81 May Not Be Comparable To €(1.60) Estimate, Sales €1.24B May Not Be Comparable To €587.81M Estimate
Earnings Week Ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and More